• Recently, JPMorgan upgraded Ameren Corporation’s rating to Overweight, citing strong data center-driven electricity demand and a more constructive regulatory environment in Missouri that together support the utility’s long-term earnings profile.
• The upgrade underscores how Ameren’s high-voltage transmission project wins and growing data center workloads could meaningfully influence its earnings mix and capital deployment priorities.
• Next, we’ll examine how this more supportive regulatory backdrop might reshape Ameren’s investment narrative built around data center demand and grid modernization.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 13 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Ameren Investment Narrative Recap

To own Ameren, you need to be comfortable with a regulated utility leaning heavily on data center load growth, grid upgrades and a supportive Missouri framework to justify its large capital plan. JPMorgan’s upgrade reinforces that regulatory risk appears more balanced near term, while the main catalyst remains timely approval and execution of transmission and data center projects; the biggest current risk is still that data center demand or regulatory decisions fall short of the assumptions underpinning those investments.

Among recent announcements, Ameren’s selection by MISO to build about US$1.3 billion of long-range transmission projects stands out, because it connects directly to the data center and grid-modernization narrative highlighted by JPMorgan. These projects help translate higher expected workloads and a constructive regulatory backdrop into potential rate base growth, but they also increase Ameren’s exposure to future regulatory lag, cost recovery debates and any slowdown in large-load customer commitments.

Yet behind this supportive regulatory tone, investors should still be aware of the risk that data center demand and project approvals...

Ameren's narrative projects $10.6 billion revenue and $1.9 billion earnings by 2029. This requires 7.6% yearly revenue growth and about a $0.4 billion earnings increase from $1.5 billion today.

Uncover how Ameren's forecasts yield a $120.40 fair value, a 13% upside to its current price.

Exploring Other Perspectives

Two fair value estimates from the Simply Wall St Community span roughly US$96 to US$120 per share, underscoring how differently individual investors view Ameren’s prospects. Set that against the reliance on data center driven load growth and regulatory approvals, and it becomes clear why you may want to compare multiple viewpoints before deciding how Ameren fits into your portfolio.

Explore 2 other fair value estimates on Ameren - why the stock might be worth as much as 13% more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Ameren research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Ameren research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ameren's overall financial health at a glance.

Looking For Alternative Opportunities?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.
• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.